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White blood cell differential count and adnexal mass size may predict 
potential malignancies in laparoscopic surgery
Bo Ram Choi, M.D.1, Yeon Hong, M.D.1, Jeong Hye Baek, M.D.1, Ji Su Huh, M.D.1, Min Young Jang, M.D.1,
Young Eun Jeun, M.D.1, Kyoung Eun Lee, M.D.1, Kyung Jin Lim, M.D.2, Hyo In Yang, M.D.2, 
Young Sik Choi, M.D.2, Hye Yeon Kim, M.D.3, Seok Kyo Seo, M.D.2, SiHyun Cho, M.D.1, Byung Seok Lee, M.D.1
1Department of Obstetrics and Gynecology, Gangnam Severance Hospital, 
2Department of Obstetrics and Gynecology, Severance Hospital, Yonsei University College of Medicine, Seoul, 
3Department of Obstetrics and Gynecology, Yongin Severance Hospital, Yongin, Korea
Objective: We investigated the clinical value of using preoperative differential white blood cell (WBC) count to predict the 
potential for malignancy of adnexal masses in laparoscopic surgery. 
Methods: The electronic medical records of 1325 patients who underwent laparoscopic surgery for adnexal masses be-
tween July 2005 and December 2008 were analyzed retrospectively.
Results: Of 1325 patients, 30 (2.3%) had adnexal masses with malignant potential. Analysis of differential WBC count, 
neutrophil to lymphocyte ratio (NLR), neutrophil to monocyte ratio (NMR), serum CA 125, mass size showed that only cyst 
size was significantly different between patients with potentially malignant adnexal masses, those with benign disease 
(averages of 9.45 cm vs. 6.23 cm, p=0.001). Further analysis was performed using a combination of various markers and 
multiplication of cyst size and NMR yielded the highest area under the curve, at 0.711(95% confidential interval 
0.619~0.806, p<0.001), with a sensitivity and specificity of 86.7% and 48.3% respectively, at a cut off value of 67.23. 
These values were also significantly different between patients with potentially malignant adnexal masses, and dermoid 
cyst or endometrioma (p=0.038 and 0.002 respectively, by analysis of variance, post hoc test).
Conclusion: Preoperative measurement of NMR in conjunction with cyst size may be used as a simple, non invasive mark-
er for predicting the malignant potential of adnexal masses before laparoscopic surgery. 
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Introduction
Operative laparoscopy has become the gold standard treat-
ment for several benign gynecological conditions. Compared 
to laparotomy, laparoscopy is associated with less post-
operative pain, shorter hospital stay, and more rapid return to 
normal activity.1) Although the safety and effectiveness of lap-
aroscopic management has been well established for small- 
and moderate-sized ovarian cysts, the use of laparoscopic sur-
gery for treatment of adnexal mass remains controversial be-
cause of the possibility of discovering an unexpected ovarian 
malignancy during surgery.2-6) Since spillage of tumor or cyst-
ic contents is common during laparoscopic surgery, and is 
thought to be an important prognostic factor for malignancy, 
appropriate patient selection is critical.5) Although subjective 
evaluation of transvaginal sonography and color Doppler im-
ages of adnexal masses has shown to be fairly good method for 
discriminating between benign and malignant adnexal masses, 
it depends on the experience of sonologists, and the diagnostic 
accuracy of borderline ovarian tumors is lower even by an ex-
perienced sonologist.7-11) Preoperative assessment of adnexal 
masses by serum tumor markers would be more feasible and 
objective method, however, none of serologic markers has not 
yet reached an adequate level of accuracy. 
Recently, the role of the immune system in disease cessation 
or progression has been examined, and hematological markers 
such as white blood cells (WBCs) and neutrophil-to-lymphocyte 
ratio (NLR) have been proposed as diagnostic or prognostic 
factors for a variety of cancers, including ovarian cancer.12-15) 
However, use of these simple hematologic markers for cor-
rectly identifying the risk of malignant adnexal tumors, and 
selecting low risk tumors for laparoscopic surgery has not yet 
been assessed. Therefore, the aim of this study was to evaluate 
differential WBC counts in patients with adnexal masses man-
aged laparoscopically, and to investigate which markers, ei-
ther alone or in combination with other clinical markers, can 
be used to identify potentially malignant adnexal masses be-
fore laparoscopic surgery. 
Materials and Methods
We conducted a retrospective review of the electronic medi-
cal records of 1325 patients who underwent elective laparo-
scopic surgery for adnexal masses, with subsequent patho-
logical evaluation, between July 2005 and December 2008. 
This study was approved by the ethics committee of Gangnam 
Severance Hospital, and Institutional Review Board approval 
was obtained.
Of 1325 patients, 1295 patients had pathologically con-
firmed benign adnexal masses. Of these, 667 patients (50.3%) 
had endometriosis, 370 (27.9%) had dermoid cysts, 116 
(8.8%) had serous cystadenoma and 141 patients (10.6%) had 
mucinous cystadenoma. Potentially malignant adnexal masses 
were pathologically confirmed for 30 patients (2.3%), includ-
ing 27 cases of borderline ovarian tumor and three cases of 
ovarian cancer. Of the 27 patients with borderline ovarian tu-
mors, 14 were diagnosed with a mucinous tumor and 10 with a 
serous tumor. The remaining three included one case of mixed 
germ cell tumor, one case of ovarian steroid cell tumor, and 
one case of granulose cell tumor. The three cases of ovarian 
cancer included one case of endometrioid adenocarcinoma, 
one case of papillary serous ovarian cancer, and one case of 
mucinous cystadenocarcinoma. 
Differential WBC counts and CA-125 levels were recorded 
from full blood counts routinely performed the day before 
surgery. Differential WBC counts were analyzed by an 
ADVIA 120/2120 Hematology system (Bayer HealthCare, 
Diagnostics Division, Tarrytown, NY, USA), and serum 
CA-125 levels were measured with CA125 II ECLIA 
(electrochemiluminescence immunoassay) on a Roche/Hitachi 
Modular Analytics E170 (Roche Diagnostics, Tokyo, Japan). 
WBC differential count and serum CA-125 levels were ex-
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Table 1. Clinical characteristics of patients
Benign adnexal mass (n=1295) Potentially malignant adenxal mass (n=30) p-value
Age 34.92±10.92 37.13±13.01 0.274
Gravidarum 1.61±3.35 2.10±2.17 0.427
Parity 0.89±2.97 1.22±1.34 0.533
Size of the mass (cm) 6.35±3.28 9.45±4.88 0.001
Values are expressed as mean±standard deviation.
Table 2. Mean and area under the receiver operating characteristic curves (AUC) of differential WBC counts, combined markers and 
serum CA-125 by study group
Benign adnexal mass (n=1295)
Adnexal mass of malignant 
potentials (n=30)
p-value AUC (95% CI)
WBC 6452.70±2024.28 6880.67±2747.02 0.257 0.526 (0.424~0.629)
Neutrophil 3934.35±1831.88 4418.00±2805.97 0.355 0.523 (0.418~0.628)
Lymphocyte 1961.88±662.33 1898.09±518.96 0.601 0.495 (0.391~0.600)
Monocyte 309.47±116.76 299.94±91.89 0.657 0.497 (0.396~0.599)
Eosinophil 135.52±134.05 141.29±112.41 0.815 0.557 (0.465~0.649)
Basophil 33.78±27.85 35.00±18.98 0.812 0.564 (0.481~0.649)
CA-125 (IU/mL) 43.42±97.86 41.97±48.49 0.935 0.530 (0.440~0.619)
NLR 2.26±1.63 2.65±2.51 0.407 0.532 (0.430~0.649)
NMR 13.67±7.16 14.94±6.75 0.338 0.564 (0.459~0.669)
Values are expressed as mean±standard deviation; CI, confidence interval; NLR, neutrophil-to-lymphocyte ratio; NMR, neutrophil-to-monocyte 
ratio.
pressed as the mean±standard deviation of each group. The 
neutrophil-to-lymphocyte ratio (NLR) was defined as the ab-
solute neutrophil count divided by the absolute lymphocyte 
count and the neutrophil-to-monocyte ratio (NMR) was de-
fined as absolute neutrophil count divided by the absolute 
monocyte count. Tumor size was calculated and recorded by 
maximum diameter in centimeters, and expressed as the 
mean±standard deviation, from either a preoperative ultra-
sound examination and/or abdominal and pelvic computed to-
mography scan. 
The differences in means between groups were compared 
using one-way analysis of variance, post-hoc tests, or 
Student’s t-test, where appropriate. The sensitivity and specif-
icity of each marker was assessed using receiver operating 
characteristic (ROC) curves.16) The area under the ROC curve 
was calculated as a measure of the ability of each potential 
marker to discriminate between potentially malignant adnexal 
masses and healthy controls. An area under the curve (AUC) 
of 0.5 indicated classifications assigned by chance. ROC were 
plotted to find the optimal cutoff values for maximum sensi-
tivity and specificity. The SPSS 12.0 package (SPSS Inc, 
Chicago, IL, USA) was used for statistical analysis and p<0.05 
was considered to be statistically significant.
Results
The clinical characteristics of the study subjects are shown 
in Table 1. The overall mean age of the participants was 
34.97±10.97. The mean age of patients with benign adnexal 
masses was 34.92±10.92 years, and the mean age of patients 
with potentially malignant adnexal masses was 37.13±13.01 
years. No significant differences in clinical characteristics 
were noted between the two groups, except for adnexal mass 
size, with the mean size of potentially malignant adnexal 
masses significantly higher than that of benign tumors 
(9.45±4.88 cm vs. 6.35±3.28 cm, p=0.001). 
Mean WBC differential counts are shown in Table 2. 
Neutrophil counts increased, and lymphocyte and the mono-
cyte counts decreased in patients with potentially malignant 
adnexal masses compared to patients with benign adnexal 
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Table 3. Diagnostic sensitivity and specificity of mass size multiplied by WBC differentials, serum CA-125 and combined markers in 
patients with potentially malignant adnexal masses 
AUC (95% CI) Sensitivity (%) Specificity (%) Cutoff value p-value
WBC 0.450 (0.313~0.587) 10.0 92.7 64540.00 0.474
Neutrophil 0.680 (0.574~0.786) 50.0 86.4 40247.24 0.001
Eosinophil 0.644 (0.552~0.736) 50.0 73.9  1001.13 0.007
Basophil 0.679 (0.592~0.767) 50.0 77.9   278.75 0.001
CA-125 (IU/mL) 0.692 (0.612~0.771) 76.7 49.9   146.80 <0.001
NLR 0.685 (0.590~0.779) 53.3 79.6    19.10 0.001
NMR 0.711 (0.619~0.806) 86.7 48.3    67.23 <0.001
CI, confidence interval; NLR, neutrophil-to-lymphocyte ratio; NMR, neutrophil-to-monocyte ratio.
Fig. 2. Mean values of cyst size multiplied by neutrophil-to-mono-
cyte ratio (NMR) by study group. The values were significantly 
higher for adnexal masses with malignant potential, than for der-
moid cysts and endometrioma, by ANOVA and post-hoc test.
Fig. 1. Receiver operating characteristic curves of cyst size multi-
plied by neutrophil-to-monocyte ratio. Differential diagnosis be-
tween patients with benign adnexal masses excluding endome-
triomas and adnexal masses with malignant potentials is shown. 
masses, but the differences were not significant. Serum 
CA-125 was also not significantly different between the 
groups. Both NLR and NMR showed higher values in patients 
with potentially malignant adnexal masses, although differ-
ences were not significant. To compare the predictive useful-
ness of differential WBC counts, serum CA-125, NLR and 
NMR, we examined ROC curves. Basophil counts and NMR 
showed the highest AUC, with 0.564 (Table 2). Since no sin-
gle marker displayed a sufficient AUC, and since only cyst 
size showed significant differences between the two patient 
groups, we decided to use a combination marker that included 
cyst size. Markers with an AUC above 0.5 were multiplied by 
cyst size, and the ROC was reevaluated for each marker (Table 
3). The combination of NMR and cyst size showed the highest 
AUC, at 0.711 (95% confidence interval of 0.619~0.806), 
with a sensitivity of 86.7% and specificity of 48.3% at a 
cut-off value of 67.23, with p<0.001 (Table 3, Fig. 1). Positive 
and negative predictive values were 3.7% and 99.4% 
respectively. The combination of basophil count and cyst size 
showed an AUC of 0.679 (95% confidence interval of 
0.592~0.767) with a sensitivity of 50.0% and specificity of 
77.9%, at a cut-off value of 278.75. Positive and negative pre-
dictive values were 5.0% and 98.5% respectively The sensi-
tivity of serum CA-125 multiplied by cyst size was 76.7% and 
NMR and size of adnexal masses in laparoscopy
- 36 -
specificity was 49.9%, at a the cutoff value of 146.80. Positive 
and negative predictive values were 3.8% and 98.8% 
respectively.
The combined value of NMR and cyst size was further eval-
uated according to adnexal mass histological type. The mean 
combined values were 92.59±9.90 for dermoid cyst, 
80.03±89.71 for endometrioma, 111.37±88.17 for serous cys-
tadenoma, 100.39±85.31 for mucinous cystadenoma, and 
138.82±87.34 for adnexal mass (Fig. 2). Differences between 
groups were statistically significant (p<0.001 using analysis 
of variance). Post-hoc tests discriminated between the ob-
served differences, showing that the combined value was sig-
nificantly higher for adnexal masses with malignant potential 
than for dermoid cysts or endometrioma (p=0.038 and 
p=0.002, respectively), while the serous cystadenoma group 
showed a significantly higher level than the endometrioma 
group (p=0.002).
Discussion
In this retrospective review of patients with adnexal masses 
managed laparoscopically, we demonstrated that a combined 
marker of NMR and the cyst size was significantly increased 
in patients with potentially malignant adnexal masses, and that 
this marker had a sensitivity of 86.7% and a specificity of 
48.3%, at a cutoff value of 67.23. 
Although operative laparoscopy is the gold standard for 
treating adnexal masses because of technical and surgical 
progress, treating ovarian tumors laproscopically remains 
controversial, because of concern about discovering an un-
recognized ovarian malignancy or tumor spillage, either of 
which lead to an inability to proceed with an immediate stag-
ing laparotomy, and a delay in treatment. While laparotomy 
with a longitudinal median incision is advocated ovarian can-
cer patients to ensure adequate surgical staging and removal of 
all obvious tumor sites, some studies indicated the feasibility 
and effectiveness of laparoscopic management of borderline 
ovarian tumors, since most patients with these tumors have an 
excellent prognosis.17,18) However, even in borderline ovarian 
tumors, proper staging is important, as the cornerstone of cor-
rect treatment. Proper staging can be achieved only by per-
forming a midline laparotomy and exploring the complete ab-
dominal cavity for extraovarian implants.19) In any case, an ac-
curate preoperative diagnosis appears to be the best approach, 
in which the patient is referred to an oncological surgeon, and 
laparotomy is used only when necessary.
The value of preoperative ultrasound examination for se-
lecting women with adnexal masses for laparoscopic surgery 
has been examined, and preoperative ultrasound assessment 
predicted the successful outcome of laparoscopic surgery with 
a sensitivity of 98% and a specificity of 79%.7) However, the 
accuracy of ultrasound is dependent on operator skill and sub-
jective assessment.20) Also, a retrospective evaluation of 21 
possible prognostic models to distinguish benign from malig-
nant adnexal masses showed that for any model, diagnostic 
performance is much lower when used by investigators other 
than the initators.21) Pattern recognition for preoperative ultra-
sound diagnosis of borderline ovarian tumors is difficult, lead-
ing to fairly high specificity, but a failure to see typical fea-
tures in one third of cases, which are typically misdiagnosed as 
benign.10) 
Use of serological markers for preoperative detection of ad-
nexal masses with malignant potential before laparoscopic 
surgery would ideally be more objective. However, no single 
marker, including serum CA-125, has shown sufficient sensi-
tivity and specificity to be used for early detection of ovarian 
cancer. Recent studies focus on using serum tumor markers in 
combination with serum CA-125. These combined markers 
have increased sensitivity and specificity.22) Therefore, in this 
study, we evaluated combinations of preoperative differential 
WBC count, serum CA-125 levels, and cyst size, to see if com-
bined markers could predict the malignant potential of adnexal 
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masses before laparoscopic surgery. 
Inflammatory cells can both suppress and stimulate tumor 
growth, and WBC differential count is a diagnostic and prog-
nostic indicator for various cancers including ovarian 
cancers.12-15) In contrast to previous works on ovarian cancer, 
neutrophilia accompanied by relative lymphocytopenia was 
not prominent in our study,14,15) probably because most of the 
adnexal masses with malignant potential in our study were 
borderline ovarian tumors with low potential for malignancy, 
and a majority of the benign cysts included endometrioma, 
which were associated with increased NLR.23) Instead, neutro-
philia accompanied by relative monocytopenia, NMR, and in-
creased basophil count showed the highest AUC among the 
WBC differentials. NMR combined with cyst size showed the 
highest AUC, and was significantly higher in patients with po-
tentially malignant adnexal masses than in those with benign 
conditions. 
The association between the monocyte count and adnexal 
mass with malignant potential, especially for borderline ovar-
ian tumors with low malignancy potential, is not fully under-
stood and must be clarified. Although a higher monocyte 
count in peripheral blood is associated with poor prognosis of 
ovarian cancer and melanoma, little is known about the associ-
ation between monocyte count and borderline ovarian tumors 
with low malignancy potential.14,24) Previous investigations on 
the role of monocyte chemoattractant protein (MCP-1) in-
dicated that MCP-1 is a potent chemotactic factor that attracts 
circulating monocytes and macrophages to the site of tumor 
growth and inflammation, and is secreted by a variety of hu-
man tumors including ovarian cancer.25,26) MCP-1 levels in se-
rum and ascites were increased in patients with ovarian cancer, 
compared to control patients.25,26) These findings suggest that 
MCP-1 has a role in recruiting circulating monocytes to be-
come tumor-associated macrophages in ovarian cancer. 
However, previous work on MCP-1 mRNA expression in 
ovarian cancer tissue showed that only one borderline tumor 
of three was positive for MCP-1 mRNA expression, in stromal 
and focal epithelial tissue.25) This finding suggests that the role 
and function of MCP-1 in borderline ovarian tumor is different 
its role in malignant ovarian cancer, and warrants further study 
on the relationship between MCP-1 expression, peripheral 
monocyte levels, and tumor-associated macrophage activity in 
borderline ovarian tumors.
Adnexal mass size is an independent predictor of malig-
nancy risk.27) Our results showed that the size of potentially 
malignant adnexal masses was significantly increased com-
pared to benign cysts. However, many large ovarian tumors 
are benign. A large prospective study involving 1304 women 
with unilocular cysts who underwent operation over a 10-year 
period showed benign pathology in 93.2% of cases with diam-
eters of 8 cm or more.28) If size is the only criterion on which 
the operative approach is based, many women with large be-
nign tumors will have an unnecessary laparotomy, rather than 
laparoscopic surgery. Therefore, in this study, we used cyst 
size in conjunction with WBC differential count to discrim-
inate adnexal masses with malignant potential from benign 
cysts. Assessment of this combined marker appears to be less 
dependent on operator skill, and can be achieved more easily 
and objectively.
A limitation of this study is its retrospective design, so our 
findings must be confirmed with prospective studies. Also, 
there exists a selection bias since when preoperative findings 
such as ultrasound examination and/or abdominal and pelvic 
computed tomography scan suggested malignancy, the choice 
of surgical procedure was laparotomy, rather than laparoscopy 
Although subgroup analysis revealed significant differences 
between endometrioma and adnexal masses with malignant 
potential, changes in WBC differential counts are involved in 
the inflammatory process. Therefore, the possibility of an 
acute inflammatory process such as tubo-ovarian abscess 
should be considered before applying these markers for pre-
dicting malignant potential prior to laparoscopic surgery. 
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In conclusion, our study has shown that the multiplication 
of cyst size with NMR may be useful in predicting malignant 
potential before laparoscopic surgery. The major advantage of 
using these markers in practice is that they are easily obtained 
and can be interpreted from routine complete blood counts 
taken during preoperative evaluation, without additional costs 
or testing. Although the sensitivity and specificity of these 
markers are not sufficient enough to use them as novel mark-
ers, they can be helpful in making decisions to conduct further 
evaluations, such as computed tomography or magnetic reso-
nance imaging, on the adnexal mass before laparoscopy. This 
could lead to a more meticulous approach during surgery to 
prevent tumor spillage, the decision to have an oncological 
surgeon available for complete staging if necessary, and may 
even minimize the number of unexpected malignancies en-
countered during laparoscopic surgery. 
국문 요약 
목  적: 
복강경 수술에서 자궁 부속기 종양의 악성 가능성을 예측하
기 위해 수술 전 백혈구 분포를 이용한 임상적 가치를 연구하
고자 한다.
방  법: 
2005년 07월부터 2008년 12월 사이 자궁 부속기 종양으로 
복강경 수술을 한 1325명의 전자 의료 기록을 소급하여 분석
하였다. 
결  과:
1325명의 환자 중 30명(2.3%)에서 악성 가능성이 있는 자궁 
부속기가 있었으며, 백혈구 분포, 중성구 대 단구의 비율
(NMR), 혈청 CA-125, 종양 크기를 분석한 결과, 악성 가능성 
있는 자궁 부속기를 가진 환자와 양성 질환을 가진 환자 사이
에서 낭종 크기만이 중요한 차이가 있었다(평균 9.45 cm 대 
6.23 cm, p=0.001). 다양한 표지자의 조합을 이용해 추가적으
로 분석하였으며, 낭종 크기와 NMR의 곱이 0.711로 가장 높
은 곡선 아래의 면적을 내었으며, 민감도 86.7%, 특이성 
48.3%, 절단 값 67.23을 보였다 (95% 신뢰 구간 0.619~0.806, 
p<0.001). 이 수치 또한 악성 가능성 있는 자궁 부속기를 가진 
환자와 유피낭종 또는 자궁내막종을 가진 환자들 사이에서 중
요한 차이가 있었다(p=0.038, p=0.02). 
결  론: 
수술 전 NMR 수치와 낭종 크기의 조합은 복강경 수술 이전 
자궁 부속기 종양의 악성 가능성을 예측하는 간단하고, 비침습
적인 표지자로 사용될 수 있다.
중심단어: 복강경, 자궁부속기 종양, 악성 가능성, 백혈구 분
포 크기
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